Patent · US Active

Use of icaritin for the preparation of composition for treating cancer

US9301942B2 · kind B2 · utility

0Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 30, 2014
Grant dateApr 5, 2016
Priority date
Expiry dateMay 30, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.